THE VALUE OF QUANTITATIVE MEASUREMENT OF HBEAG AND HBSAG BEFORE INTERFERON-ALPHA TREATMENT OF CHRONIC HEPATITIS-B IN CHILDREN

被引:18
|
作者
BURCZYNSKA, B
MADALINSKI, K
PAWLOWSKA, J
WOYNAROWSKI, M
SOCHA, J
GERLICH, WH
WILLEMS, WR
WOZNIEWICZ, B
STACHOWSKI, J
机构
[1] UNIV GIESSEN,INST MED VIROL,D-35392 GIESSEN,GERMANY
[2] CHILD HLTH CTR,DEPT CLIN IMMUNOL,WARSAW,POLAND
[3] CHILD HLTH CTR,DEPT GASTROL,WARSAW,POLAND
[4] CHILD HLTH CTR,DEPT PATHOMORPHOL,WARSAW,POLAND
[5] SECOND CLIN CHILDRENS DIS,POZNAN,POLAND
来源
JOURNAL OF HEPATOLOGY | 1994年 / 21卷 / 06期
关键词
HBV DNA; PREDNISONE TREATMENT; QUANTITATION OF HBSAG; TITER OF HBEAG;
D O I
10.1016/S0168-8278(05)80624-5
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Serum concentrations of KBsAg, HBeAg and hepatitis B virus DNA were measured quantitatively before interferon treatment in 23 children (17 boys, 6 girls) suffering from chronic hepatitis B, and correlated to the outcome of the treatment. Five children remained HBsAg- and HBeAg-positive throughout the treatment and 6 months after the end of the treatment (non-responders), 12 children eliminated HBeAg but not HBsAg (partial responders) and six eliminated HBeAg and HBsAg (complete responders). The five non-responders had significantly higher initial HBsAg and HBeAg concentrations and significantly lower alanine aminotransferase levels than the partial or complete responders. The six complete responders had significantly lower HBsAg concentrations than the partial or non-responders, and seemed to be younger. No significant difference in HBV DNA levels was found in the three response groups. These data suggest that quantitative assays of HBsAg and HBeAg are particularly useful in selecting patients with chronic hepatitis B for interferon therapy. (C) Journal of Hepatology.
引用
收藏
页码:1097 / 1102
页数:6
相关论文
共 50 条
  • [1] EFFICACY OF INTERFERON-ALPHA IN THE TREATMENT OF CHILDREN WITH CHRONIC HEPATITIS-B
    RUIZMORENO, M
    RUA, MJ
    GARCIAAGUADO, J
    QUIROGA, JA
    PORRES, JC
    MORALEDA, G
    CARRENO, V
    PEDIATRIC RESEARCH, 1990, 27 (05) : 535 - 535
  • [2] LOSS OF HBSAG AFTER INTERFERON-ALPHA TREATMENT - CURE OF CHRONIC HEPATITIS-B VIRUS
    DAVIS, GL
    HEPATOLOGY, 1991, 14 (05) : 953 - 954
  • [3] MONITORING OF INTERFERON-ALPHA TREATMENT IN CHRONIC ACTIVE HEPATITIS-B
    LAVANCHY, D
    MAYERAT, C
    FREI, PC
    BLUM, AL
    JOURNAL OF HEPATOLOGY, 1992, 16 (1-2) : 245 - 246
  • [4] CURRENT STATUS OF INTERFERON-ALPHA IN THE TREATMENT OF CHRONIC HEPATITIS-B
    BRAKEN, JB
    KOOPMANS, PP
    VANMUNSTER, IP
    GRIBNAU, FWJ
    PHARMACEUTISCH WEEKBLAD-SCIENTIFIC EDITION, 1992, 14 (04) : 167 - 173
  • [5] RECOMBINANT INTERFERON-ALPHA(2A) HASTENS THE RATE OF HBEAG CLEARANCE IN CHILDREN WITH CHRONIC HEPATITIS-B
    BARBERA, C
    BORTOLOTTI, F
    CRIVELLARO, C
    COSCIA, A
    ZANCAN, L
    CADROBBI, P
    NEBBIA, G
    PILLAN, MN
    LEPORE, L
    PARRELLA, T
    DASTOLI, G
    BRUNETTO, MR
    BONINO, F
    HEPATOLOGY, 1994, 20 (02) : 287 - 290
  • [6] TREATMENT OF CHRONIC HEPATITIS-B WITH RECOMBINANT INTERFERON-ALPHA VERSUS RECOMBINANT INTERFERON-ALPHA PLUS LEVAMISOLE
    BOSCH, O
    MORALEDA, G
    CASTILLO, I
    CARRENO, V
    JOURNAL OF HEPATOLOGY, 1993, 19 (03) : 437 - 441
  • [7] HEPATITIS-B AND INTERFERON-ALPHA
    FEIST, D
    MONATSSCHRIFT KINDERHEILKUNDE, 1994, 142 (06) : 456 - 456
  • [8] INTERFERON-ALPHA RETREATMENT IN CHRONIC ACTIVE HEPATITIS-B
    TEUBER, G
    DIENES, HP
    ZUMBUSCHENFELDE, KHM
    GERKEN, G
    HEPATOLOGY, 1993, 18 (04) : A258 - A258
  • [9] A RANDOMIZED CONTROLLED TRIAL OF LYMPHOBLASTOID INTERFERON-ALPHA IN PATIENTS WITH CHRONIC HEPATITIS-B LACKING HBEAG
    FATTOVICH, G
    FARCI, P
    RUGGE, M
    BROLLO, L
    MANDAS, A
    PONTISSO, P
    GIUSTINA, G
    LAI, ME
    BELUSSI, F
    BUSATTO, G
    BALESTRIERI, A
    RUOL, A
    ALBERTI, A
    HEPATOLOGY, 1992, 15 (04) : 584 - 589
  • [10] COMBINATION OF RECOMBINANT INTERFERON-ALPHA AND INTERFERON-GAMMA IN TREATMENT OF CHRONIC HEPATITIS-B
    CARRENO, V
    MORA, I
    LANCET, 1987, 2 (8567): : 1086 - 1086